Clinical Trial Update: Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating TXA127 to reduce acute graft-versus-host disease in patients undergoing double umbilical cord blood transplantation has been w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• TXA127

Snippet

Sponsor: Tarix Pharmaceuticals | Conditions: Hematologic Malignancies | Phase 2 | Status: WITHDRAWN